Table 2 Average HR and ΔHR within the predefined subgroups
subgroup | mean HR 1st recumbent phase (bpm) | mean HR standing phase (bpm) | mean HR 2nd recumbent phase (bpm) | ∆HRa (%) |
|---|---|---|---|---|
symptoms during mASTb (n = 80) | 67 (64–69) | 85 (81–88) | 67 (64–70) | 32 (29–36) |
no symptoms during mASTb (n = 123) | 67 (65–68) | 84 (81–86) | 66 (64–67) | 30 (28–33) |
technical issuesb (n = 36) | 68 (65–71) | 83 (78–87) | 67 (63–70) | 28 (24–33) |
no technical issuesb (n = 166) | 66 (65–68) | 84 (82–87) | 66 (64–68) | 32 (30–34) |
human medicine (n = 145) | 66 (65–68) | 85 (83–87) | 66 (64–67) | 33 (30–35) |
dental medicine (n = 14) | 65 (60–69) | 79 (72–86) | 65 (61–69) | 25 (17–32) |
midwifery (n = 13) | 72 (62–82) | 88 (78–99) | 73 (61–86) | 27 (18–36) |
pharmacy (n = 45) | 66 (63–69) | 82 (78–86) | 66 (63–69) | 28 (23–32) |
femalesc (n = 47) | 67 (63–71) | 84 (79–89) | 68 (63–72) | 29 (24–33) |
malesc (n = 11) | 68 (62–73) | 81 (76–87) | 67 (62–72) | 23 (15–31) |